bluebird bio recommended ahead of trial updates at JPMorgan JPMorgan recommends owning shares of bluebird bio ahead of upcoming clinical trial updates. The firm notes initial data from the Phase 1/2 HGB-205 study evaluating LentiGlobin in beta-thalassemia patients will be presented on June 14 at the European Hematology Association. JPMorgan has an Overweight rating on the stock with a $44 price target.
Credit Suisse to hold a conference Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 13 at 11 am; not all company presentations may be webcasted. Webcast Link